Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

61.60
-1.4000-2.22%
Post-market: 61.60-0.0043-0.01%16:06 EDT
Volume:517.90K
Turnover:31.57M
Market Cap:2.97B
PE:-25.61
High:63.04
Open:62.25
Low:59.47
Close:63.00
52wk High:72.64
52wk Low:9.63
Shares:48.16M
Float Shares:27.63M
Volume Ratio:1.63
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4052
EPS(LYR):-2.3824
ROE:-33.17%
ROA:-22.08%
PB:7.24
PE(LYR):-25.86

Loading ...

LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

TIPRANKS
·
May 16

Mbx Biosciences Inc : Stifel Raises Target Price to $56 From $50

THOMSON REUTERS
·
May 12

MBX Biosciences price target raised to $86 from $76 at Citizens

TIPRANKS
·
May 12

MBX Biosciences CMO Salomon Azoulay disposes of USD 2.68 million common shares

Reuters
·
May 12

BUZZ-U.S. STOCKS ON THE MOVE-Barrick Mining, Lumentum, Tesla

Reuters
·
May 12

BUZZ-MBX rises on obesity drug data showing monthly dosing potential

Reuters
·
May 11

MBX Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
May 11

Stock Track | MBX Biosciences Soars 5.92% Intraday on Positive Obesity Drug Data and Analyst Upgrades

Stock Track
·
May 11

MBX Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating

MT Newswires Live
·
May 11

MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim

TIPRANKS
·
May 11

MBX Biosciences Highlights Positive Phase 1 Obesity Data

TIPRANKS
·
May 11

MBX Biosciences reports 7% mean weight loss at 8 weeks in MBX 4291 Phase 1 trial

Reuters
·
May 11

Mbx Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for Mbx 4291 Supporting Potential for Once-Monthly Dosing

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - Ind-Enabling Studies for Mbx 5765 Expected to Begin in Q2 2026

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 12-Week Phase 1 Mad Part C Data on Track for Q4 2026

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 Generally Well Tolerated With Minimal Gi Events at 8 Weeks

THOMSON REUTERS
·
May 11

Mbx Biosciences Inc - 4291 Phase 1 Data Show Mean Weight Loss of 7% at 8 Weeks

THOMSON REUTERS
·
May 11

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

GlobeNewswire
·
May 11

Top MBX Biosciences Executive Makes Notable Stock Move

TIPRANKS
·
May 09